Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCap-xx Regulatory News (CPX)

Share Price Information for Cap-xx (CPX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0775
Bid: 0.075
Ask: 0.08
Change: -0.0055 (-6.63%)
Spread: 0.005 (6.667%)
Open: 0.083
High: 0.083
Low: 0.0775
Prev. Close: 0.083
CPX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Subscription to raise £1.75 million

5 Nov 2018 07:00

RNS Number : 2691G
CAP-XX Limited
05 November 2018
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 ("MAR"). IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

 

5 November 2018

 

 

CAP-XX Limited

 

("CAP-XX" or the "Company")

 

Subscription to raise £1.75 million

 

CAP-XX, a world leader in the design and manufacture of supercapacitors and energy management systems, is pleased to announce that the Company has raised gross proceeds of £1.75 million (approximately A$3.0m after fees), by way of a subscription (the "Subscription") of 20,588,236 new ordinary shares (the "Subscription Shares") at a price of 8.5 pence per share (the "Subscription Price"). The Subscription Price represents a discount of approximately 8 per cent. to the closing mid-market price on 2 November 2018, the last practicable date prior to the release of this announcement. The Subscription Shares are to be issued within the Company's existing share allotment authorities, in line with CAP-XX's dilution policy which was approved by shareholders on 23 November 2017.

 

The proceeds of the Subscription will be used to advance the Company's strategy to increase product sales and to complete additional licence agreements.

 

Application has been made to the London Stock Exchange for the Subscription Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and dealings in the Subscription Shares will commence at 8:00 am on 9 November 2018.

 

The Subscription Shares will be issued credited as fully paid and will rank in full for all dividends and other distributions declared, made or paid in respect of the Company`s ordinary shares ("Ordinary Shares") after the date of Admission and will otherwise rank pari passu in all respects with the Company's existing Ordinary Shares.

 

The enlarged issued share capital of the Company following the issue of the Subscription Shares will be 323,752,709 Ordinary Shares with voting rights. The Company does not hold any Ordinary Shares in Treasury.

 

Following Admission, the above figure of 323,752,709 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the share capital of the Company.

 

Commenting on the Subscription, Anthony Kongats, Chief Executive of CAP-XX said, "We are delighted to receive continued support from our institutional shareholders in supporting this funding round which will accelerate the expansion of our direct sales channels for supercapacitors alongside sales through our growing portfolio of licences."

 

Information for Distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the Product Governance Requirements) may otherwise have with respect thereto, the Subscription Shares have been subject to a product approval process by Allenby Capital Limited, which has determined that the Subscription Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, investors should note that: the price of the Subscription Shares may decline and investors could lose all or part of their investment; Subscription Shares offer no guaranteed income and no capital protection; and an investment in Subscription Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Subscription. Furthermore, it is noted that, notwithstanding the Target Market Assessment, only investors who have met the criteria of professional clients and eligible counterparties have been procured. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to Subscription Shares.

 

 

For further information, please contact:

CAP-XX Limited

 

Anthony Kongats (Chief Executive Officer)

+61 (0) 2 9428 0139

 

 

Allenby Capital Limited (Nominated Adviser and Broker)

 

David Hart / Alex Brearley

+44 (0) 20 3328 5656

 

 

Kreab (Financial PR)

 

Robert Speed

 

+44 (0) 20 7074 1800

More information is available at www.cap-xx.com 

 

Notes to editors

About CAP-XX

CAP-XX (LSE: CPX) is a world leader in the design and manufacture of thin, flat supercapacitors and energy management systems used in portable and small-scale electronic devices, and large supercapacitor based modules used in larger applications such as automotive and renewable energy. The unique feature of CAP-XX supercapacitors is their very high power density and high energy storage capacity in a space-efficient prismatic package. These attributes are essential in power-hungry consumer and industrial electronics, and deliver similar benefits in automotive and other transportation applications. For more information about CAP-XX, visit www.cap-xx.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEEAPFLEDNPFFF
Date   Source Headline
7th May 202410:10 amRNSHolding(s) in Company
7th May 20247:00 amRNSTrading Update
1st May 202411:08 amRNSHolding(s) in Company
30th Apr 20245:00 pmRNSTotal Voting Rights
25th Apr 20249:24 amRNSHolding(s) in Company
24th Apr 20245:04 pmRNSN05/24 - CAP-XX Limited - Restoration of trading
23rd Apr 20248:36 amRNSResult of General Meeting
8th Apr 20249:12 amRNSLitigation with Kyocera AVX settled
28th Mar 20245:00 pmRNSTotal Voting Rights
27th Mar 20248:22 amRNSSuspension of trading
27th Mar 20247:29 amRNSN04/24 - CAP-XX Limited - Suspension of trading
25th Mar 20247:00 amRNSResult of Retail Offer and Total Voting Rights
22nd Mar 20247:00 amRNSResult of Placing and Notice of General Meeting
21st Mar 20244:40 pmRNSREX Retail Offer
21st Mar 20244:35 pmRNSProposed Placing and Subscription to raise £2.0m
21st Mar 20249:00 amRNSLitigation Settlement Agreement with Tesla, Inc
19th Mar 202412:31 pmRNSHolding(s) in Company
18th Mar 20242:56 pmRNSHolding(s) in Company
15th Mar 202412:50 pmRNSHolding(s) in Company
15th Mar 20247:07 amRNSHolding(s) in Company
14th Mar 20247:00 amRNSUpdate on litigation
13th Mar 20247:00 amRNSCorporate Update
12th Mar 20247:00 amRNSRetirement of CFO
28th Feb 20247:00 amRNSUpdate on litigation and trading
19th Feb 20247:00 amRNSCessation of appeals process
1st Feb 20247:00 amRNSInterim Results
29th Jan 20247:00 amRNSUpdate on Patent Infringement
22nd Jan 202412:57 pmRNSChange of Joint Broker
10th Jan 20247:02 amRNSUpdate on IP and appeals process
29th Dec 20231:00 pmRNSTotal Voting Rights
21st Dec 20237:00 amRNSTrading Update
18th Dec 20237:00 amRNSUpdate on Patent Infringement
7th Dec 20237:00 amRNSCAP-XX finalises two new patents
5th Dec 20237:00 amRNSIssue of Shares and Director/PDMR Shareholdings
1st Dec 20237:00 amRNSUpdate re. R&D rebate and other matters
29th Nov 20237:00 amRNSHolding(s) in Company
22nd Nov 202311:29 amRNSHolding(s) in Company
3rd Nov 20239:05 amRNSResult of AGM and Directorate Change
3rd Nov 20237:05 amRNSAGM Trading Update
26th Oct 20232:05 pmRNSHolding(s) in Company
13th Oct 20239:45 amRNSNotice of AGM
4th Oct 20237:00 amRNSExpansion of sales operations
29th Sep 20237:00 amRNSAudited results for the year ended 30 June 2023
14th Sep 202312:29 pmRNSHolding(s) in Company
2nd Aug 20237:00 amRNSPre-close Trading Update and Notice of Results
31st Jul 20239:53 amRNSHolding(s) in Company
18th Jul 202310:27 amRNSUpdate on Patent Infringement
30th Jun 20235:00 pmRNSTotal Voting Rights
13th Jun 20237:00 amRNSHolding(s) in Company
9th Jun 20237:53 amRNSAppointment of Chief Executive Officer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.